Table 3 Xerostomia and xerophthalmia prevalence, assessment methods and others related variables
Relation studied | Study. year | Xerostomia | Xerophthalmia | Anticholinergic Drug | |||
|---|---|---|---|---|---|---|---|
Assessment methods | Prevalence (%) | Assessment methods | Prevalence (%) | Most frequently prescribed anticholinergic drugs | Exposure (%) | ||
Anticholinergic drug use and peripheral effects | Thomson WM. 1993 | Patient’s self-reports | 20% | No tested | No tested | No data | 3.9% |
Katz IR. 1988 | Patient’s self-reports | 39% | No tested | No tested | Antihistamines | 24.5% | |
Ness J. 2006 | Patient’s self-reports | 51.60% | Patient’s self-reports and eye tears prescription | 9.90% | Antihistamines | 27.1% | |
Desoutter A. 2012 | Patient’s self-reports | 37.30% | No tested | No tested | No Data | 27.8% | |
Anticholinergic burden and peripheral effects | Rudolph JL.2008 | Retrospective cohort: documented in the medical record | 10.60% | Retrospective cohort: documented in the medical record | 13.6% | No Data | 46.9%a |
Prospective cohort: Patient’s self-reports | 44.40% | Prospective cohort: Patient’s self-reports | 5.1% | No Data | 29.9%a | ||
Kersten H. 2012 | Clinical assesment: STc | No Data | No tested | No tested | Antidepressants | 100%b | |
Kersten H. 2013 | Clinical assesment: STc | No Data | No tested | No tested | Furosemide | 100%b | |
Tiisanoja A. 2017 | Clinical assesment: SSDd | 21.40% | No tested | No tested | No Data | 49%a | |
Inkeri NM. 2019 | Patient’s self-reports | No Data | Patient’s self-reports | No Data | Antihistamines | 8.9%a | |
Lavrador M. 2021 | Clinical assesment: STc | 59.2% | Clinical assesment: SchTe | 34% | No data | 68%f 83.6%b 34.8%a 78%g | |